Merck & Co., Inc. (ETR:6MK)
Germany
· Delayed Price · Currency is EUR | Market Cap | 178.99B |
| Revenue (ttm) | 59.14B |
| Net Income (ttm) | 16.13B |
| Shares Out | n/a |
| EPS (ttm) | 6.36 |
| PE Ratio | 11.10 |
| Forward PE | 9.30 |
| Dividend | 2.91 (4.06%) |
| Ex-Dividend Date | Jun 16, 2025 |
| Volume | 1,786 |
| Average Volume | 3,204 |
| Open | 72.10 |
| Previous Close | 72.20 |
| Day's Range | 70.50 - 72.20 |
| 52-Week Range | 65.50 - 120.00 |
| Beta | 0.40 |
| RSI | 54.45 |
| Earnings Date | Jul 29, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap
Merck's recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent cliff. The pharmaceutical leader has made an agreement to acquire the COPD d...
FDA Approves BRAVECTO QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administr...
FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced t...
SeaStar Medical's QUELIMMUNE Wins Prestigious Award From The National Kidney Foundation, Former Winners Include Names Like Janssen, Merck and Otsuka
When it comes to unmet needs in the nephrology space, acute kidney injury remains a significant concern. That's particularly true regarding pediatric AKI – each year, about 4,000 children with AKI req...
Merck's doravirine/islatravir under FDA review for HIV
U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for dor...
U.S. FDA Accepts New Drug Application for Merck's Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--U.S. FDA Accepts New Drug Application for Merck's DOR/ISL Once-Daily Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1.
Verona Pharma (VRNA) Downgraded as Merck Plans $10B Acquisition | VRNA Stock News
Verona Pharma (VRNA) Downgraded as Merck Plans $10B Acquisition | VRNA Stock News
US pharma giant Merck snaps up London lung specialist Verona Pharma for £7.5bn
Merck is looking to strengthen its respiratory treatments as part of efforts to reduce dependence on its blockbuster cancer treatment.
Measuring Options Activity in MRK & XLV: Healthcare Levels to Watch
Rick Ducat turns to the healthcare sector on today's options analysis. He starts with the SPDR Health Care ETF (XLV), noting the recent breakdown of a head and shoulders pattern and potential for both...
Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps
Kazia Therapeutics (NASDAQ: KZIA) on Wednesday reported preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, Merck & Co Inc’s (NYSE: MRK) K...
P/E Ratio Insights for Merck & Co
Looking into the current session, Merck & Co Inc. (NYSE: MRK) shares are trading at $82.37, after a 1.23% increase. Moreover, over the past month, the stock increased by 4.43% , but in the past year,...
Major deals involving U.S. drugmakers and biotechs over the past decade
Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda.
Undercovered Dozen: Roku, Merck, Chevron And More
Merck to Buy Verona Pharma for Around $10 Billion
Merck agreed to buy respiratory drugmaker Verona Pharma for about $10 billion as it tries to make up for huge expected patent losses. Sales could fall by $18 billion over the next five years.
VRNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verona Pharma plc Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verona Pharma plc (NASDAQ: VRNA) to Merck for $107.00 per American Depository Share is fair to Verona shareholders. ...
Merck Buys Verona Pharma: A Good Deal, But M&A Spree Must Continue
Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my updated look at MRK and VRNA stock.
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 0.1% on Wednesday. Shares of Verona Pharma plc (NASDAQ: VRNA) rose sharply during Wednesday's session after Merck announced it will ac...
Merck has struck a roughly $10 billion deal to buy Verona Pharma
The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.
META Stake in Ray-Ban & Oakley Maker, MRK Acquiring VRNA, TMUS Downgrade
Meta Platforms (META) is moving to eyewear. As Diane King Hall explains, the Mag 7 giant is seeking to build its own A.I.
Merck to buy Verona for $10 billion ahead of Keytruda patent expiration
CNBC's Angelica Peebles reports on themes emerging in the pharma space.
Merck to buy Verona for $10 billion ahead of Keytruda patent expiration
CNBC's Angelica Peebles reports on themes emerging in the pharma space.
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Merck & Co. Inc. (NYSE: MRK) agreed on Wednesday to acquire Verona Pharma plc (NASDAQ: VRNA) for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. ...
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Merck & Co. Inc. MRK agreed on Wednesday to acquire Verona Pharma plc VRNA for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ADS represents ...